CureGate Español

EGFR lung cancer clinical trials in Los Angeles

This page lists recruiting research studies near Los Angeles for people with non-small cell lung cancer that has an EGFR change, and for the families helping them.

Each study decides who can join. CureGate’s free service helps people understand which studies may be worth asking an oncologist about.

Start the free quick check →Four questions. No records needed. Call Aria (855) 606-1679CureGate’s AI assistant, in English or Spanish.

Clinical trials are research and are not guaranteed to help. CureGate does not provide medical advice.

Start from the biomarker result, if there is one

Pick what fits best. “I don’t know” is a perfectly good answer.

EGFR exon 19 deletion or L858R EGFR exon 20 insertion Another EGFR change KRAS G12C A different result (ALK, ROS1, MET, RET, HER2 or other) Tested, but not sure of the result Not tested, or I don’t know

What is an EGFR change?

EGFR is a gene that helps cells grow and divide. In some lung cancers the gene has a change (a mutation). The most common EGFR changes are exon 19 deletions and L858R. Exon 20 insertions are less common and are often studied separately.

Doctors find EGFR changes with biomarker testing (also called molecular, genomic or next-generation sequencing testing) on a tumor sample or a blood sample.

There are FDA-approved medicines for EGFR-changed lung cancer, and research studies are testing newer approaches, including studies for people who have already received osimertinib or another EGFR medicine.

Not sure about biomarker results? That is common.

Many people do not know whether biomarker testing was done, or what it found. You do not need to know to get started.

Places to look: a report from a lab such as Foundation Medicine, Tempus, Caris or Guardant; the pathology section of the patient portal; or ask the oncology office, “Was comprehensive biomarker testing done, and can I get a copy of the report?”

If you choose to share records with CureGate, CureGate’s research team can help find the biomarker results and explain what they mean for study options.

Start the quick check without a result → Call Aria (855) 606-1679

29 recruiting EGFR lung cancer studies near Los Angeles

Data from ClinicalTrials.gov as of November 3, 2026. Grouped by what each study’s eligibility criteria ask for. Study status can change at any time; titles are shown as registered. Confirm details with each study team.

Studies for common EGFR changes (exon 19 deletion or L858R)

  1. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Phase
    2
    Recruiting in
    Lancaster, Long Beach, South Pasadena, Upland
    Last updated

  2. Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

    Phase
    not listed
    Recruiting in
    Torrance
    Last updated

  3. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    Phase
    1
    Recruiting in
    Beverly Hills, Duarte, Orange, Santa Monica
    Last updated

  4. Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

    Phase
    3
    Recruiting in
    Los Alamitos, Los Angeles, Orange, Santa Monica
    Last updated

Studies for people who already received osimertinib or another EGFR medicine

  1. A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

    Phase
    2
    Recruiting in
    Orange
    Last updated

  2. Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

    Phase
    3
    Recruiting in
    El Segundo, Fountain Valley, Fullerton, Irvine, Newport Beach
    Last updated

  3. Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

    Phase
    2
    Recruiting in
    Duarte
    Last updated

  4. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    Phase
    1/2
    Recruiting in
    Los Angeles
    Last updated

  5. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    Phase
    2/3
    Recruiting in
    Irvine, Orange
    Last updated

  6. A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

    Phase
    2/3
    Recruiting in
    Duarte, Irvine, Los Angeles, Newport Beach, Santa Monica, Upland
    Last updated

  7. A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

    Phase
    2/3
    Recruiting in
    Duarte, Irvine
    Last updated

  8. Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

    Phase
    1/2
    Recruiting in
    Los Angeles
    Last updated

  9. Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

    Phase
    1
    Recruiting in
    Beverly Hills, Los Angeles, Torrance
    Last updated

  10. Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

    Phase
    2
    Recruiting in
    Beverly Hills, Los Angeles, Torrance
    Last updated

  11. Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

    Phase
    2
    Recruiting in
    Los Angeles
    Last updated

Studies for EGFR exon 20 insertions

  1. First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

    Phase
    1/2
    Recruiting in
    Duarte, Huntington Beach, Irvine
    Last updated

  2. A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

    Phase
    3
    Recruiting in
    Santa Monica
    Last updated

  3. A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

    Phase
    2
    Recruiting in
    Duarte
    Last updated

  4. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    Phase
    1/2
    Recruiting in
    Duarte, Huntington Beach, Irvine, Long Beach
    Last updated

Other EGFR studies

  1. A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

    Phase
    2
    Recruiting in
    Duarte, Irvine
    Last updated

  2. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    Phase
    3
    Recruiting in
    Fullerton, Los Angeles, Orange
    Last updated

  3. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Phase
    3
    Recruiting in
    Duarte, Huntington Beach, Irvine, Lancaster
    Last updated

  4. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

    Phase
    2
    Recruiting in
    Glendale
    Last updated

  5. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Phase
    2
    Recruiting in
    Los Angeles
    Last updated

  6. A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

    Phase
    1
    Recruiting in
    Los Angeles
    Last updated

  7. Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

    Phase
    2
    Recruiting in
    Duarte, Irvine
    Last updated

  8. A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

    Phase
    1/2
    Recruiting in
    Irvine
    Last updated

  9. A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

    Phase
    1
    Recruiting in
    Los Angeles, Newport Beach, Santa Monica
    Last updated

  10. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

    Phase
    2
    Recruiting in
    Los Angeles
    Last updated

How CureGate helps

Answer four quick questions to see how many recruiting studies may fit. No records are needed.

Aria, CureGate’s AI assistant, can call back to help with the next steps. Aria may ask whether biomarker testing was done; “I don’t know” is fine.

CureGate’s research team reviews everything before any study site is contacted, and nothing is shared without permission.

Start the free quick check →Four questions. No records needed. Call Aria (855) 606-1679CureGate’s AI assistant, in English or Spanish.

Support and education

Patient groups such as the LUNGevity Foundation, GO2 for Lung Cancer and the American Cancer Society offer free education about biomarker testing and lung cancer.

Frequently asked questions

Do I need to know the exact EGFR result to ask about a study?

No. Many people are not sure of their results. You can still use CureGate’s quick check, and if you choose to share records later, CureGate’s research team can help find the biomarker report.

Why are exon 20 insertion studies listed separately?

Exon 20 insertions behave differently from the more common EGFR changes, so many studies enroll them on their own. They have their own group on this page when ClinicalTrials.gov lists them near Los Angeles.

Are there studies after osimertinib?

Some studies are designed for people whose cancer grew after osimertinib or another EGFR medicine. When ClinicalTrials.gov lists them near Los Angeles, they appear in their own group above. Only the study team can confirm whether someone can join.

What is biomarker testing?

Biomarker testing looks for gene changes or proteins in a tumor or blood sample. Results are often in a report from a lab such as Foundation Medicine, Tempus, Caris or Guardant, or in the pathology section of the medical record. An oncologist can explain which tests were done.

What does CureGate do with the answer I pick on this page?

It stays in your browser for this visit so the quick check can start in the right place. It is not used for advertising, and nothing is shared with a study site unless you say so.

Is CureGate running these studies?

No. CureGate is an independent matching service. The studies are run by their sponsors and research sites, and a listing on this page is not a recommendation of any study.

Does CureGate’s help cost anything?

No. CureGate’s service is free for patients and families. Ask each study team what the study covers.

Clinical trials are research and are not guaranteed to help. CureGate does not provide medical advice.